China NMPA Drug Inspection - Shaanxi Momed Pharmaceutical Co., Ltd. - Laxative Granules

The Hubei Provincial Food and Drug Administration released a Drug Quality Bulletin in October 2019, announcing the findings from quality sampling inspections conducted in the first quarter of 2015. The detailed list of non-compliant products was originally published on June 26, 2015. These inspections covered 642 batches from drug manufacturing enterprises, hospital preparations, and pharmaceutical packaging materials across Hubei Province. Out of these, 24 batches, representing 3.7% of the total, failed to meet established quality standards.

The main issues identified included deviations in product properties, incorrect identification (e.g., microscopic characteristics), insufficient or inconsistent content determination, and failures in various tests such as dissolution, moisture content, fill weight, particle size, and purity. Companies implicated in these findings included Macheng Jiuzhou Traditional Chinese Medicine Development Co., Ltd., Hubei Qiangkang Traditional Chinese Medicine Pieces Co., Ltd., and Qingdao Huanghai Pharmaceutical Co., Ltd., among others. These violations contravened the "Chinese Pharmacopoeia 2010 Edition," national drug standards, and other relevant regulatory requirements.

Consequently, local food and drug administrations were directed to conduct thorough investigations and take appropriate enforcement actions under the "Drug Administration Law of the People's Republic of China." Authorities were also mandated to investigate the origins of any counterfeit drugs and enhance subsequent sampling and testing of affected products to uphold drug quality and safety.